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ABSTRACT
Congenital heart defects are the most common birth defects in
humans, and those that affect the proper alignment of the outflow
tracts and septation of the ventricles are a highly significant cause of
morbidity and mortality in infants. A late differentiating population of
cardiac progenitors, referred to as the anterior second heart field
(AHF), gives rise to the outflow tract and the majority of the right
ventricle and provides an embryological context for understanding
cardiac outflow tract alignment and membranous ventricular septal
defects. However, the transcriptional pathways controlling AHF
development and their roles in congenital heart defects remain
incompletely elucidated. Here, we inactivated the gene encoding the
transcription factor MEF2C in the AHF inmice. Loss ofMef2c function
in the AHF results in a spectrum of outflow tract alignment defects
ranging from overriding aorta to double-outlet right ventricle and
dextro-transposition of the great arteries. We identify Tdgf1, which
encodes a Nodal co-receptor (also known as Cripto), as a direct
transcriptional target of MEF2C in the outflow tract via an AHF-
restricted Tdgf1 enhancer. Importantly, both theMEF2C and TDGF1
genes are associated with congenital heart defects in humans. Thus,
these studies establish a direct transcriptional pathway between the
core cardiac transcription factor MEF2C and the human congenital
heart disease gene TDGF1. Moreover, we found a range of outflow
tract alignment defects resulting from a single genetic lesion,
supporting the idea that AHF-derived outflow tract alignment
defects may constitute an embryological spectrum rather than
distinct anomalies.
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INTRODUCTION
Congenital heart defects are the most common birth defects in
humans, affecting ∼0.8% of all live births, and defects in the
alignment of the cardiac outflow tracts (OFTs) cause a diverse group
of serious cyanotic malformations (Anderson et al., 1974; Hoffman
and Kaplan, 2002). Cells from the anterior second heart field, also
referred to as the anterior heart field (AHF), are added to the arterial
pole of the heart after its initial formation and form all of the
mesoderm-derived components of the cardiac OFT and the majority
of the right ventricle (RV) (Black, 2007; Kelly, 2012). The addition
of cells from the AHF is likely to provide the embryological basis
for OFT alignment and membranous septal defects (Neeb et al.,
2013). However, despite the identification of the AHF and its role in
OFT development, the transcriptional and signaling pathways that
function in this progenitor population and its derivatives and the
possible involvement of these pathways in congenital heart defects
remain incompletely elucidated.
The MADS box transcription factor MEF2C is a key component
in the network regulating AHF development (Black, 2007; Dodou
et al., 2004). The Mef2c gene is required for heart development in
the mouse, and mice that lackMef2c die around embryonic day (E)
10.0 due to failure in cardiac morphogenesis and a failure of the
heart to undergo rightward looping (Lin et al., 1997). This
morphogenetic defect has been interpreted as a failure of cells
from the AHF to be properly deployed to the heart (Nakazawa et al.,
2011; Verzi et al., 2005). MEF2C has also been associated with
congenital OFT defects in human patients (Kodo et al., 2012), but
the specific function and transcriptional targets of MEF2C in the
AHF and its derivatives are largely unknown.
Teratocarcinoma-derived growth factor 1 (TDGF1; also known as
Cripto) is a Nodal signaling co-receptor (Ding et al., 1998; Schier
and Shen, 2000). Nodal is a TGFβ family member ligand that
signals through core TGFβ receptors in association with an
additional co-receptor of the EGF-CFC family, such as TDGF1,
to activate downstream intracellular signaling (Shen and Schier,
2000). Tdgf1-null mouse embryos exhibit striking defects in
mesoderm formation and anterior-posterior patterning, resulting in
early embryonic lethality and concomitant absence of cardiac
marker gene expression (Ding et al., 1998; Xu et al., 1999). Recent
studies identified mutations in human TDGF1 associated with
isolated congenital heart defects, including membranous ventricular
septal defects and conotruncal alignment defects (Roessler et al.,
2008;Wang et al., 2011), suggesting that errors in this component of
Nodal signaling might be involved in developmental defects that are
restricted to cardiac development.
To define pathways downstream of MEF2C important for the
development of the AHF and its derivatives, we inactivated Mef2c
exclusively in the AHF and found that Mef2c AHF knockout mice
die at birth with severe cyanosis, ventricular septal defects and a
spectrum of OFT alignment defects. Tdgf1 expression was
completely abolished in the OFT in the absence of MEF2C, and
we identified a transcriptional enhancer from Tdgf1 with activity
that completely mimics endogenous Tdgf1 expression in AHF
derivatives. Importantly, we found that the Tdgf1 AHF enhancer is
a direct transcriptional target of MEF2C via a conserved consensus
MEF2 site in the enhancer. Thus, these studies establish a
requirement for MEF2C for OFT development and define a direct
transcriptional pathway between MEF2C and the congenital heart
disease gene Tdgf1.Received 12 May 2015; Accepted 19 January 2016
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RESULTS AND DISCUSSION
MEF2C is required for proper OFT alignment
We deleted Mef2c exclusively in the AHF and its derivatives using
Mef2c-AHF-Cre (Verzi et al., 2005) (Fig. S1). This approach
resulted in a greater than 98.5% reduction ofMef2c transcripts in the
RV and OFT by E10.5 (Fig. S1). Mice with deletion of Mef2c in
the AHF (referred to hereafter asMef2cAHF-KO or CKO) were born at
the expectedMendelian frequency (Fig. S1), but approximately half
displayed profound cyanosis and died shortly after birth. Control
neonates showed normal positioning of the outflow vessels and
proper septation of the ventricles (Fig. 1A). By contrast, 21/36 of
Mef2cAHF-KO mice that were examined in detail had significant
cardiac defects, ranging from isolated membranous ventricular
septal defect (VSD) to more extensive OFT alignment defects with
associated VSD (Fig. 1, Table 1). The spectrum of OFT alignment
defects observed in Mef2cAHF-KO mice included overriding
aorta with stenotic or atretic pulmonary artery and associated
membranous VSD (Fig. 1B), reminiscent of the defects observed in
human patients with tetralogy of Fallot (Anderson et al., 2013). A
significant number of neonatal Mef2cAHF-KO mice also presented
with transposition of the great arteries (TGA; Fig. 1C) and double-
outlet right ventricle (DORV; Fig. 1D).
Mef2cAHF-KO neonates displayed nearly completely penetrant
abnormalities in the semilunar valve leaflets, even in the absence of
other obvious defects (Fig. 1, Table 1), suggesting that MEF2C
might play a role in endocardial cushion maturation and valve
development. Alternatively, disrupted blood flow might have
created hemodynamic alterations in Mef2cAHF-KO fetuses, leading
to the observed valve dysmorphogenesis (Menon et al., 2015). To
examine the semilunar valves in additional detail, we created 3D
reconstructions of the OFTs in Mef2cAHF-KO and control neonates
and measured the volume of the valve leaflets and the length of
the OFT vessels. The volume of the aortic valve leaflets was
significantly smaller inMef2cAHF-KO mice than in controls [control,
1.00±0.22 (n=6); Mef2cAHF-KO, 0.58±0.16 (n=7); P=0.006;
values are relative mean volume±s.d.; see also renderings of 3D
Fig. 1. Mef2c function in the AHF is required for proper OFT alignment. (Aa-d) Normal alignment of the aorta (Ao) and pulmonary artery (PA) in control
neonatal mice. RV, right ventricle; LV, left ventricle. (B-D) Subsets of Mef2cAHF-KO neonatal mice displayed a tetralogy of Fallot-like phenotype, including
hypoplastic pulmonary artery, ventricular septal defect (VSD, arrowheads), overriding aorta, and hypertrophic right ventricle (Ba-d); dextro-transposition of the
great arteries (d-TGA) with VSD (Ca-d); or double-outlet right ventricle (DORV) with or without d-TGA (Da-d). Note that allMef2cAHF-KO mice displayed thickened
and club-shaped semilunar valves, as shown in Bd-Dd.
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reconstructions in Fig. S2]. We also found that the aorta was
significantly shorter inMef2cAHF-KO mice than in controls [control,
245±28 (n=6);Mef2cAHF-KO, 139±50 (n=7); Student’s t-test, P=0.005;
values are mean pixel length±s.d.].
The phenotypic variability seen inMef2cAHF-KOmice is intriguing,
and there are several possible explanations. These experiments were
conducted in a mixed genetic background, suggesting that modifier
genes might influence the penetrance or severity of the phenotype
(Doetschman, 2009). We believe that this is the most likely
explanation for the phenotypic variability. It is also possible that the
precise timing or pattern of Cre excision of Mef2c may have varied
among embryos. However, we consider this unlikely since excision
was alreadyessentially complete in theOFTandRVbyE10.5 (Fig. S1).
More generally, our observations support the idea that a single
primary genetic lesion can result in a range of OFT defects, which in
clinical practice are often considered discrete entities (Dorfman and
Geva, 2006; Johnson, 2010). Our data also support the idea that
complex alignment phenotypes might form a continuous spectrum
of related OFT alignment disorders, as others have also proposed
based on observations from other mouse genetic models,
particularly for Tbx1 and related pathways (Brown et al., 2004;
Racedo et al., 2015; Rana et al., 2014; Vincentz et al., 2005).
Tdgf1 is a direct transcriptional target of MEF2C in the
developing OFT
Analyses of Mef2cAHF-KO embryos showed the first evidence of an
OFT alignment phenotype at E12.5, when disruptions of the normal
relationship of the aorta and the pulmonary artery to each other
could be seen in ∼50% ofMef2cAHF-KO embryos (Fig. S3). To gain
additional insight into the cellular or molecular basis of the OFT
alignment defects seen in Mef2cAHF-KO mice, we analyzed gene
expression, apoptosis, proliferation, and the contribution of the
Mef2c-AHF-Cre lineage to the heart in Mef2cAHF-KO and control
embryos at E10.5 (Fig. S4). By this stage, Mef2cAHF-KO embryos
had no detectableMef2c expression in the OFT, but this was still just
prior to the onset of any obvious OFT defects. We observed no
statistically significant changes in apoptosis or proliferation
between Mef2cAHF-KO and control embryos, nor did we observe
any apparent differences in the contribution of the Mef2c-AHF-Cre
lineage (Fig. S4). To gain insight into changes in gene expression in
Mef2cAHF-KO mutants, we performed RNA-seq on OFTs isolated
from E10.5 wild-type and mutant embryos. These results identified
Tdgf1 as the single most dysregulated gene, being reduced by∼98%
in the OFTs of Mef2cAHF-KO embryos in RNA-seq (wild type, 92
FPKM; Mef2cAHF-KO, 2 FPKM; Student's t-test, P<0.001). This
result was confirmed by qPCR (wild type, 1.00±0.25;Mef2cAHF-KO,
0.0066±0.0019; ±s.d.; n=8 each; Student's t-test, P<0.001).
The nearly complete dependence of Tdgf1 expression in the OFT
on the transcription factor MEF2C suggested the possibility of a
direct transcriptional relationship. Therefore, we scanned the Tdgf1
locus for putative transcriptional enhancers using a combination of
bioinformatics approaches and analyses of open chromatin
(Dubchak and Ryaboy, 2006; Thurman et al., 2012). This led to
the identification of a single transcriptional enhancer in the Tdgf1
locus with robust activity in the derivatives of the AHF (Fig. 2).
Importantly, β-galactosidase activity directed by the Tdgf1 AHF
enhancer (Fig. 2H-J) was consistent with endogenous Tdgf1
transcript expression (Fig. 2B-D) and almost perfectly mimicked
the β-galactosidase activity directed by a Tdgf1lacZ knock-in allele
(Ding et al., 1998; Fig. 2E-G), suggesting that we had identified a
bona fide Tdgf1 enhancer sufficient to recapitulate Tdgf1 expression
in the heart during the time when the AHF is contributing to the
development of the RV and OFT.
Crossing mice harboring a stable Tdgf1 enhancer-lacZ transgene,
referred to as Tdgf1::lacZ (Fig. 2A), onto a Mef2c-null background
resulted in loss of transgene expression (Fig. 3A,B), indicating that
the enhancer was completely dependent on MEF2C for activity.
Similarly, expression from the endogenous Tdgf1 locus was also
dependent on MEF2C (Fig. 3C,D). Importantly, the Tdgf1 AHF
enhancer contains a single, perfect consensus MEF2 binding site
(Fig. 2A), and this MEF2 site was specifically bound by MEF2C in
EMSA (Fig. 3E). Furthermore, mutation of the MEF2 site in the
context of the full-length Tdgf1 enhancer almost completely
abolished enhancer activity in transgenic embryos in vivo
(Fig. 3F,G). Taken together, these data establish that MEF2C
directly regulates Tdgf1 expression in the AHF and its derivatives
via the MEF2 site in the enhancer.
The Tdgf1 enhancer sequence also contains three consensus NKE
sequences that have been previously suggested, based on in vitro
studies, to function as NKX2-5 binding sites (Behrens et al., 2012).
However, neither mutation of the three NKE elements in the Tdgf1
enhancer nor crossing Tdgf1::lacZ onto an Nkx2-5-null background
had a discernible effect on transgene expression (data not shown),
suggesting that NKX2-5 is not required for Tdgf1 enhancer function
in vivo.
Implications of a MEF2C-TDGF1 pathway for congenital
heart disease
Importantly, the data presented here establish a direct transcriptional
relationship between two genes associated with OFT alignment
defects (Kodo et al., 2012; Roessler et al., 2008; Wang et al., 2011).
This direct transcriptional relationship suggested the possibility that
Mef2c and Tdgf1might exhibit a genetic interaction. To test this idea
explicitly, we intercrossed Mef2c+/− and Tdgf1+/− mice to generate
compound heterozygotes. Interestingly,Mef2c+/−;Tdgf1+/− double-
heterozygous mice were viable and presented with no apparent
congenital heart defects (Table S1). The lack of an overt phenotype
might be because double heterozygosity does not eliminate Tdgf1
Table 1. Penetrance of the spectrum of phenotypes in Mef2cAHF-KO neonates
OFT valve defects associated with:
Genotype n Normal
Isolated OFT
valve defects VSD only
VSD+overriding
aorta (ToF-like) VSD+DORV VSD+d-TGA
Mef2c-AHF-CreTg/0;Mef2cflox/− (CKO) 36 1 14 8 5 3 5
Mef2cflox/+ (wt) 4 4 0
Mef2cflox/− 5 5 0
Mef2c-AHF-CreTg/0;Mef2cflox/+ (het) 13 13 0
For each neonate, transverse sections were cut through the entire heart and phenotypes were catalogued in a blinded fashion. CKO, Mef2cAHF-KO conditional
knockout; het,Mef2cAHF-KO heterozygous; wt, wild type; OFT, outflow tract; VSD, membranous ventricular septal defect; ToF, tetralogy of Fallot; DORV, double-
outlet right ventricle; d-TGA, dextro-transposition of the great arteries.
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expression from the OFT or lower it enough to uncover an OFT
phenotype. It is possible that subtle, incompletely penetrant OFT
defects might occur, but we observed no evidence of this (data not
shown). Considering that theMef2cAHF-KO phenotype is only∼50%
penetrant on an outbred background (Table 1), failure to observe an
overt phenotype inMef2c+/−;Tdgf1+/− double-heterozygous mice is
not surprising and does not diminish the significance of the direct
transcriptional relationship betweenMEF2C and Tdgf1 identified in
these studies. TDGF1 has been associated with VSDs and OFT
alignment defects in humans (Roessler et al., 2008; Wang et al.,
2011), but the pathways associated with TDGF1 in heart
development were previously unknown. MEF2C has also been
implicated as having a possible role in OFT defects in humans.
Kodo et al. (2012) identified a single sequence variant in human
MEF2C (A103V) in a single patient with isolated congenital heart
disease. Although this observation is not conclusive, taken together
with the work presented here it supports a role for an MEF2C-
TDGF1 pathway in human congenital OFT defects.
Fig. 2. Tdgf1 is expressed in the AHF and the activity of a cardiac-specific
enhancer mimics endogenous expression. (A) The murine Tdgf1 locus and
Tdgf1::lacZ reporter transgene. The canonical MEF2 binding site in the
enhancer is indicated. Exons are numbered. (B-D) Whole-mount in situ
hybridization for Tdgf1 in wild type (wt) at E8.5 (B), E9.5 (C), E10.5 (D).
(E-G) X-gal staining of Tdgf1lacZ/+ embryos also shows endogenous
expression of Tdgf1 from the knock-in allele at E8.5 (E), E9.5 (F), E10.5 (G).
(H-J) X-gal-stained embryos of a stable Tdgf1::lacZ transgenic line at E8.5
(H,H′), E9.5 (I,I′), E10.5 (J,J′). (H′-J′) Transverse sections of X-gal-stained
Tdgf1::lacZ transgenic embryos. Arrows indicate the OFT in all panels. Scale
bars: 100 µm.
Fig. 3. MEF2C is required for Tdgf1 enhancer activity and expression in
the heart. (A-D) Tdgf1::lacZ (A,B) and Tdgf1lacZ/+ (C,D) transgenic embryos
crossed ontowild-type (wt) (A,C) orMef2c-null (B,D) backgrounds, collected at
E8.5 and X-gal stained. Note the loss of X-gal staining in the absence ofMef2c
function (B,D). (E) EMSA of a double-stranded radiolabeled oligonucleotide
probe encompassing the Tdgf1 MEF2 site by recombinant MEF2C (lane 2).
MEF2C binding was efficiently competed by ∼30-fold excess of unlabeled self
probe (lane 3), but was not competed by∼30-fold excess of amutant version of
the probe (lane 4). Unprogrammed lysate (lacking MEF2C) is shown in lane
1. Bound MEF2C, a non-specific complex (ns) and free probe bands are
indicated. (F,G) Representative X-gal-stained E9.5 embryos harboring a wild-
type (wt) Tdgf1::lacZ transgene (F) and a Tdgf1::lacZ transgene with a
disruptedMEF2site (mMEF2) (G). 8/13Tdgf1::lacZ(wt) lines/embryos showed a
strong pattern of X-gal staining, such as in the embryo shown in F. By contrast,
2/7 independent Tdgf1::lacZ(mMEF2) founder embryos showed weak X-gal
staining, such as shown in G, and 5/7 Tdgf1::lacZ(mMEF2) founder embryos
showed no detectable X-gal staining. Arrows (A-D,F,G) mark the OFT.
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Nodal signaling is crucial for the establishment of laterality in
the early embryo, and disrupted Nodal signaling has been
implicated in human congenital heart disease (Roessler et al.,
2008; Shen, 2007). Congenital heart defects due to disrupted
Nodal signaling have generally been associated with global defects
in left-right patterning, such as heterotaxy (Bisgrove et al., 2003;
Mohapatra et al., 2009), but in light of the work presented here
it is interesting to speculate that a Nodal signaling network,
including TDGF1, might be redeployed later in heart development
to achieve local left-right or anteroposterior patterning. Importantly,
expression of Nodal ligand-encoding genes, particularly Gdf1,
continues beyond the time of gastrulation and is present at the
time and in the vicinity of the early developing heart (Rankin et al.,
2000; Wall et al., 2000). Moreover, several other downstream
components of Nodal signaling, including FOXH1 and PITX2C,
are also known to play important roles, possibly in a pathway
with MEF2C in the AHF (Ai et al., 2006; Furtado et al., 2011; von
Both et al., 2004). Alternatively, TDGF1 might function in the
OFT in a manner independent of its role as a Nodal co-receptor,
possibly as a secreted protein, as has been proposed previously (Yan
et al., 2002).
The cellular basis for the OFT shortening in Mef2cAHF-KO
neonates is unclear. It is possible that subtle defects in proliferation,
apoptosis or lineage contribution occur in a subset of embryos and
that this accounts for the incompletely penetrant phenotype at
neonatal stages, but these changes were not apparent when
analyzing all mutant embryos. Alternatively, MEF2C might
control OFT alignment and elongation via a cellular process or
molecular pathway not examined here. Further studies will be
required to elucidate additional roles of MEF2C, TDGF1, and their
downstream pathways in OFT morphogenesis.
MATERIALS AND METHODS
Mice
Mef2c-AHF-Cre, Mef2cflox/flox, Mef2c+/−, Tdgf1lacZ/+ (Tdgf1+/−), Rosa26R
and Nkx2-5-null mice have each been described previously (Ding et al.,
1998; Lin et al., 1997; Moses et al., 2001; Soriano, 1999; Verzi et al., 2005;
Vong et al., 2005). Transgenic mouse lines were generated by
oocyte microinjection as described previously (Rojas et al., 2005). To
generate Tdgf1::lacZ transgenic mice, a 5.21 kb fragment of the Tdgf1 gene
was amplified from mouse genomic DNA using primers 5′-GCCCCGC-
GGCAACCTGGGCTACTGATGGT-3′ and 5′-GGCGCGGCCGCGTG-
ATTGAGGACTTCGGAGG-3′. The product was then cloned as a
SacI-NotI fragment into plasmid p-AUG-β-gal (De Val et al., 2008) to
make plasmid Tdgf1-lacZ, which was then used for subsequent
generation of transgenic mice. The MEF2 site mutation was introduced
into the full-length 5.21 kb Tdgf1 enhancer by site-directed mutagenesis
using primers 5′-GCCATCTCTCCAGCTGCTGGGATTAAGTTTTTGA-
TGCAGATATTTTATGACAGTTG-3′ and 5′-CAACTGTCATAAAATA-
TCTGCATCAAAAACTTAATCCCAGCAGCTGGAGAGATGGC-3′.
Genotyping was performed on DNA isolated from yolk sacs or from tail
biopsies by Southern blot or PCR. All experiments using animals were
approved by the UCSF Institutional Animal Care and Use Committee and
complied with federal and institutional guidelines.
Histological analyses, X-gal staining and in situ hybridization
Section and whole-mount in situ hybridization and whole-mount X-gal
staining were performed using standard procedures, as previously described
(McCulley et al., 2008; Rojas et al., 2005). The Mef2c and Tdgf1 probes
have been described elsewhere (Anderson et al., 2015; Ding et al., 1998).
Lineage analysis using Mef2c-AHF-Cre;Rosa26R mice and analyses of
apoptosis with anti-cleaved caspase 3 (1:200) and of proliferation with anti-
phospho-histone H3 (1:200) were performed as described previously
(McCulley et al., 2008; Sinha et al., 2012).
3D reconstructions and measurements
Neonatal hearts were fixed in 4% paraformaldehyde overnight at 4°C and
then embedded in paraffin, cut into 5-µm sections, and stained with
Hematoxylin and Eosin. Images of consecutive sections were acquired using
an Olympus BX40 light microscope and were then stacked and aligned
using the Fiji version of ImageJ software. Volume and surface area
measurements were taken from 3D reconstructions using Imaris software
(Bitplane). Aorta length was measured from the base of the aortic root to the
brachiocephalic arterial branch using Fiji.
RNA sequencing (RNA-seq) and quantitative real-time PCR
(qPCR)
Embryonic OFTs were collected at E10.5 and RNAwas extracted using the
RNeasy Micro Kit (Qiagen, 74004) according to the manufacturer’s
recommendations. cDNA was generated using the Ovation RNA-Seq
System V2 (NuGen). cDNA was then fragmented to ∼200-300 bp before
ligating to barcoded TruSeq adaptors using the Encore Rapid Library
System (NuGen). Resulting libraries were sequenced on a HiSeq 2000
(Illumina). FASTQ files were aligned to the reference mouse genome
(mm9) using TopHat v1.3 (Trapnell et al., 2009). Differential expression
was determined with U-Seq version 8.0.2 (Nix et al., 2008). RNA-seq data
have been deposited in the Gene Expression Omnibus repository under
accession number GSE68147. qPCR was performed using the SYBR Green
system (Life Technologies) using the primers listed in Table S2.
Electrophoretic mobility shift assay (EMSA)
EMSAwas performed as described previously (Rojas et al., 2005). MEF2C
was transcribed and translated using the TNT Quick Coupled Transcription/
Translation System (Promega) from plasmid pCITE-MEF2C, which was
made by cloning the Mef2c coding sequence in frame into the in vitro
translation plasmid pCITE-2B (Promega). The sense strand sequences of the
Tdgf1MEF2 site (underlined) oligonucleotides used for EMSAwere:MEF2
site, 5′-GGGATCAAAAACTTAATTTTAGCAGCTGGAG-3′; mutant
MEF2 site (changes in bold), 5′-GGGATCAAAAACTTAATCCCAGC-
AGCTGGAG-3′.
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